ClinicalTrials.gg
Status unknownNCT04620395SHARPUpdated Nov 9, 2020

Percutaneous Punch Biopsy for Diagnosis of Septic and Aseptic Prosthetic Joint Failure

An interventional study of Punch biopsy in Wear of Articular Bearing Surface of Internal Prosthetic Joint, Infection Prosthetic and Infections Joint Prosthetic, sponsored by Vivantes Netzwerk für Gesundheit GmbH. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-09.

Sponsored by Vivantes Netzwerk für Gesundheit GmbH · Not applicable, Interventional, and Diagnostic

How we know

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the superiority study is to establish a reproducible, minimally invasive, cost-effective way of sample collection for microbiological and pathomorphological processing in a clinical setting with avoidance of anesthesia, multiple punctures, as well as potential deep contamination during irrigation.

Read the detailed description

The main aim of the study is to demonstrate the superiority of a punch biopsy over a joint tap to rule out or prove septic prosthesis failure and thus establish a new diagnostic method. The subsequently calculated sensitivities of the previous and the procedure are used as the main indicator. In addition, we would like to prove that the total cost of diagnosing a septic / aseptic prosthesis failure using the proposed method has socio-economic advantages over the previous algorithm.

One of the secondary objectives is the evaluation of the use of a punch biopsy for simultaneous a priori pathomorphological examination of periprosthetic soft tissue samples for the determination of wear particles. Furthermore, the study is intended to demonstrate a shortening of the time span between the first suspected diagnosis of septic prosthesis failure and its reliable exclusion / detection.

02

Conditions studied

  • Wear of Articular Bearing Surface of Internal Prosthetic Joint
  • Infection Prosthetic
  • Infections Joint Prosthetic
  • Prosthetic Joint Infection
  • Prosthetic Pain

Browse trials for

Keywords

  • prosthetic joint
  • infection
  • wear particles
  • prosthetic failure
  • antibiotics
  • biopsy
  • joint tap
03

In context

Infections

2,097 studies on the registry are indexed under Infections; 361 are open to participants now.

This study's planned enrollment of 132 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Vivantes Netzwerk für Gesundheit GmbH is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preceding implantation of a shoulder, hip or knee endoprosthesis
  • Acute or chronic pain in the joint
  • Periprosthetic fracture
  • Instability of the endoprosthesis
  • Indications of wear / insufficiency of the enclosed plastic spacers
  • Indications of metal abrasion
  • Primary misalignment of the implant

Exclusion criteria

Exclusion Criteria:

  • Confirmed periprosthetic infection
  • Proven allergy to fast-acting local anesthetics
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • No intervention
    Joint tap

    Joint tap and aspiration of synovial fluid

  • Experimental
    Punch biopsy

    Punch biopsy of a prosthetic joint and extraction of 5-7 biopsies from the synovial membrane

    Diagnostic Test: Punch biopsy

Interventions

  • Diagnostic testPunch biopsy

    A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)

06

What researchers measure

Primary outcomes

  1. Improved diagnostic accuracy

    Comparison of the specificity and sensibility of microbiological results for punch biopsies, the synovial fluid tap, pre-interventional blood Analysis, arthroscopic biopsies for confirmation/exclusion of a bacterial or fungal periprosthetic infection

    Time frame: up to 3 months

Secondary outcomes

  1. Rate of chronic periprosthetic low-grade-infections

    The incidence of hidden chronic periprosthetic infections

    Time frame: up to 3 Months

  2. Correlation of microbiological results from percutaneous Punch biopsy with intraoperative findings at Revision

    Correlation of pre-revision microbiological findings and the samples taken during the endoprosthesis replacement operation, in particular the sonicate of the prosthesis and the periprosthetic membrane (gold standard for infection diagnostics)

    Time frame: up to 6 Months

  3. Total Cost of Infection Diagnostics for various used methods

    Comparison of the respective Overall Costs for diagnostics of acute and chronic periprosthetic infections using a joint-tap, the novel punch biopsy method and arthroscopic biopsy

    Time frame: 1 Month

  4. Rate of prosthetic failure due to wear particles

    Incidence of presence of wear particles in pathomorphological examinations of the punch biopsies and the samples taken during the replacement operation

    Time frame: up to 1 month

  5. Correlation of Synovialitis score and microbiological findings

    Correlation of Synovialitis score in pathomorphological examinations and microbiological verification of an acute or chronic periprosthetic infection

    Time frame: up to 2 months

07

Study locations

1 of 1 sites recruiting
  • Vivantes Humboldt-Krankenhaus
    Berlin, 13509, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Jan 2022, 17 months after the start.

Of 276 non-industry interventional studies with no phase under Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 51. This study's planned 17 months is below that.

Counting every sponsor, half of 308 studies reached it within 24 months; a quarter within 9 and three quarters within 48.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Nov 9, 2020
StartActual
Aug 20, 2020
Primary completionEst.
Jan 31, 2022
CompletionEst.
Jun 30, 2022
Last update
Nov 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04620395
Lead sponsor
Vivantes Netzwerk für Gesundheit GmbH
Responsible party
Sponsor
First posted
Nov 9, 2020
Start date
Aug 20, 2020
Primary completion
Jan 31, 2022 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Nov 9, 2020

Study contacts

Rafal J Borucki, MD
Contact
rafal.borucki@vivantes.de
+4915129211687
Karsten Labs, PD Dr
study chair · Vivantes Humboldt Krankenhaus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion